In ATTAIN-1, treatment discontinuation as a result of gastrointestinal (GI) adverse events occurred in 3.5% to 7.0% of participants in the orforglipron groups vs only 0.4% in the placebo group
Dunzendorfer S , Rothbucher D , Schratzberger P , Reinisch N , Kahler CM , Wiedermann CJ
Pissios, P
Ongoing support Regular monitoring and follow-ups for safe, sustainable progress
In the US, diabetes is the most common reason for end-stage renal disease (ESRD), and is responsible for 40% of new dialysis patients
however, no statistically noticeable differences in the total number of retrieved and MII oocytes and fertilization rate before and after using L-carnitine supplementation were found [21]